Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials
Marizzoni M, Mirabelli P, Mombelli E, Coppola L, Festari C, Lopizzo N, et al
After 28 days, oxidation reduces potency below clinically effective levels a stability study published in the International Journal of Pharmaceutics found potency dropped to 78% at day 35 and 61% by day 42
It is designed for oral consumption in capsule form
PMID 2183788
The global prevalence of diabetes continues to rise, with projections indicating a substantial increase in disease burden over the coming decades ( Patients with T2DM and ESRD represent a particularly high-risk population characterized by advanced metabolic dysfunction, a high burden of cardiovascular disease, and extensive polypharmacy ( Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic control by increasing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and inducing weight loss